Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 742 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib MOST POPULAR New on NCI’s Websites for June 2020 June 26, 2020 Learning to Advocate for Yourself – An Important Skill! June 15, 2023 To Improve Immunotherapy, Researchers Look at Limiting Cancer’s Access to Sugar... February 18, 2021 Cancer Moonshot℠ Workshop Highlights Recent Research Advances March 4, 2020 Load more HOT NEWS Finding Purpose During Cancer: A Survivor’s Story Low-Dose Adjuvant Aspirin Decreases Incidence of Recurrence Among Patients with Resected... Cabozantinib Plus Nivolumab and Ipilimumab Results in Longer PFS in Previously... Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women...
